Načítá se...
Immunosuppressive agents for dermatological indications in the ongoing COVID‐19 pandemic: Rationalizing use and clinical applicability
The ongoing COVID‐19 epidemic has brought to the fore many concerns related to use of immunosuppressive agents (ISAs) in dermatology. While it is unclear whether the patients on ISAs for skin conditions are more prone to develop COVID‐19, and what impact the ISA may have on the clinical outcome if a...
Uloženo v:
| Vydáno v: | Dermatol Ther |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7280701/ https://ncbi.nlm.nih.gov/pubmed/32436617 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.13639 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|